Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥2 mg/L)

Background Elevated levels of high-sensitivity C-reactive protein (hsCRP) correlate with an increased risk for cardiovascular events. Combination therapy with a statin and a fibrate may be more effective than statin monotherapy for reducing hsCRP, especially in patients with mixed dyslipidemia. Obje...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical lipidology 2011-09, Vol.5 (5), p.401-407
Main Authors: Ballantyne, Christie M., MD, Davidson, Michael H., MD, Setze, Carolyn M., MS, Kelly, Maureen T., MD
Format: Article
Language:English
Subjects:
C-reactive protein
Cardiovascular
Cardiovascular risk
Dyslipidemia
Fenofibric acid
Rosuvastatin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Elevated levels of high-sensitivity C-reactive protein (hsCRP) correlate with an increased risk for cardiovascular events. Combination therapy with a statin and a fibrate may be more effective than statin monotherapy for reducing hsCRP, especially in patients with mixed dyslipidemia. Objective To characterize the treatment effects of rosuvastatin and fenofibric acid combination therapy compared with individual monotherapies in mixed dyslipidemic patients with baseline hsCRP ≥2 mg/L versus
ISSN:1933-2874
1876-4789
DOI:10.1016/j.jacl.2011.06.010